Regression of cardiac hypertrophy using angiotensin II receptor blocker in patients with chronic kidney diseases

Abstract

Objective: Cardiovascular complications proportionally increase as chronic kidney diseases (CKD) progress into chronic renal insufficiency or failure. The present study addressed whether the long-term use of angiotensin II receptor blocker (ARB) exerts a cardio-protective effect in CKD patients with mild to moderate renal damage.
Material & Methods: Fifteen patients with CKD above stage 3 were enrolled in the study. While their previous antihypertensive therapy remained unchanged, the ARB candesartan, was newly added to the concurrent therapy and the patients were followed for 12-24 months thereafter.
Results: The main results were as follows:
1) The use of ARB improved the status of BP control classifications, shifting them to the better control categories where there was less morning hypertension.
2) ARB significantly reduced the left ventricular (LV) mass index (LVMI), the relative wall thickness (RWT), the LV intra-dimension in diastole (LVIDd), and as a result, the LV ejection fraction (LVEF) improved. In parallel, the LV mass category shifted to lower categories, indicating a significant improvement.
3) The levels of BNP decreased significantly from 135.2±136.0 to 85.0±80.3pg/mL.
4) ARB reduced urinary protein excretion in all cases. Regardless of an inevitable increase in the serum creatinine (Cr) concentration, the slope of reciprocal serum Cr concentration (1/Cr) in the treatment period with ARB was significantly less steep compared to that in the run-in period.
5) Throughout the observation period, no serious side effects were found in any of the patients.
Conclusion: The present study indicated that the long-term use of ARB exerts both cardio-, and reno-protective effects in patients with advanced CKD. This agent could be especially indicative and useful not only for patients with CKD, but also for patients of CKD with cardiac hypertrophy.